Eikon Therapeutics
Drug Discovery
11open roles
$221kmedian advertised pay
13H-1B filings in 12 months
35 daysmedian time a role stays open
Overview
Eikon Therapeutics is a biopharmaceutical company that uses technology at the intersection of chemistry, engineering, computation and biology to discover new treatments for life-threatening diseases. Its discovery platform builds on microscopes that enable real time, molecular-resolution measurements of protein movement, and the company hires translational medicine, clinical data management, computational biology and research staff. The company is headquartered in Hayward, California, United States.
How Eikon Therapeutics hires
Truth index
B 75/100
Median time to fill
35 days
Ghost roles
0%
Stale roles
100%
Reposted roles
0%
Eikon Therapeutics scores B on the Alion truth index (A is best, E worst), measured over 3 open roles re-checked against its own hiring board: 0% look like ghost listings, 100% have gone stale and 0% are the same role posted again. Its roles close in a median of 35 days. It measures how much of what this employer publishes turns into a real, finite search - not the employer as a workplace. How the index is computed
Jobs
$130k – $158k per year · Equity · In office · 6+ years exp · Bachelor's Degree · Jersey City
GCP
Life Sciences
Veeva
Apply
$100k – $120k per year · In office · Contractor · 2+ years exp · Bachelor's Degree · Jersey City
Good Clinical Practice
Apply
$170k – $205k per year · Equity · In office · 4+ years exp · Jersey City
Veeva
Apply
$143k – $173k per year · Equity · In office · 6+ years exp · Bachelor's Degree · Jersey City
GCP
Life Sciences
ICH Guidelines
Veeva
MedTech
CAPA
Apply
$252k – $305k per year · Equity · In office · 10+ years exp · PhD · Jersey City
Python
GCP
Apply
$143k – $173k per year · Equity · In office · 8+ years exp · Bachelor's Degree · Jersey City
Good Clinical Practice
Apply
$270k – $326k per year · Equity · In office · 5+ years exp · Jersey City
GCP
Apply
$235k – $289k per year · Equity · In office · 15+ years exp · Bachelor's Degree · Jersey City
GCP
Life Sciences
GLP
Good Clinical Practice
Apply
$304k – $368k per year · Equity · In office · 10+ years exp · Jersey City
GCP
Apply
$183k – $221k per year · Equity · In office · 10+ years exp · Bachelor's Degree · Jersey City
Good Clinical Practice
Veeva
Apply
$213k – $257k per year · Equity · In office · 12+ years exp · Bachelor's Degree · Jersey City
GCP
Life Sciences
GLP
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$221k
Typical range
$120k – $368k
Open positions
11
11
Jobs
Junior
9.1%
Senior
63.6%
Architect
27.3%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Junior | 1 | $120k | $120k |
| Senior | 7 | $205k | $158k – $326k |
| Architect | 3 | $257k | $221k – $368k |
Highest paying role
Executive Director, Clinical Research (Medical Director)
$368k
Normalized to USD per year
All salaries at Eikon Therapeutics
By role, level and city, against the market · 11 jobs with pay
Visa sponsorship
13 ▼ 19%
H-1B filings in 12 months
3
Green card filings
$153k
Median offered salary
Who they sponsor
Data scientists
3
Software developers
2
Statisticians
2
In the register as Eikon Therapeutics, Inc., Millbrae, CA (+2 more)
Other sponsors in the same field
Genentech 
Exelixis 
Schrodinger 
Generate:Biomedicines
See 11 open roles Alert me
US Department of Labor · latest filing Jun 29, 2026 · Visa details by country
Growth
Hiring Momentum
26/100
Slowing
Open positions
11
0 opened / 0 closed in 30 days
Median time-to-fill
34 days
faster than 39% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Biotech
52% ▲
Science & Research
19% ▲
Management
7% ▼
AI/ML
4% ▼
DevOps
4% ▲
Leadership
4% ▲
Actively hiring for Biotech (+6 in 30 days)
People
Leon Chen
Director
Roger Perlmutter
Executive Officer, Director
Alfred Bowie
Executive Officer
Benjamin Thorner
Executive Officer
Dan Anderson
Executive Officer
Ashish Kheterpal
Executive Officer
Russ Berman
Executive Officer
Roy Banes
Executive Officer
Barbara Howes
Executive Officer
James Tananbaum
Director
Adam Goulburn
Director
Dror Berman
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
Technologies named in job postings at Eikon Therapeutics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
32
Postings analysed
28
Stack modernity
68/100AI adopter
Languages
Python29%
C++4%
JavaScript4%
MATLAB4%
Frameworks & libraries
React.js4%
Shiny4%
Cloud & platforms
GCP29%
Databricks7%
AWS4%
AI & ML
LLM4%
Sign in to see how your skills match this stack
Sign In
Full Eikon Therapeutics tech stack
32 technologies · by team · pay by technology · changes · similar stacks
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
EcoR1 CapitalVia a fund
Innovation EndeavorsVia a fund
Horizons VenturesVia a fund
General CatalystVia a fund
610 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Eikon Therapeutics Stock: Will Upcoming ESMO Data Rekindle Investor Interest?
Shares of Eikon Therapeutics Inc. (EIKN) trade at less than half their debut price, as the company approaches a series of potentially significant clinical milestones.
Read more
Report
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
September 3, 2026 PDF Version MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) - Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medi
Read more
Report
Eikon Therapeutics to Participate in Investor Conferences in September 2026
August 26, 2026 PDF Version MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) - Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical
Read more
Report
Eikon Therapeutics to Participate in Investor Conferences in September 2026
MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (
Read more
Report
Eikon Therapeutics to Participate in Investor Conferences in September 2026
MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (
Read more
Report
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
August 18, 2026 PDF Version Event and Webcast to be held August 20th, 2026, 9:00 AM ET MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) - Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to devel
Read more
Report
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (
Read more
Report
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
August 13, 2026 PDF Version Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon's oncology portfolio, including clinical updates for EIK1001 and EIK
Read more
Report
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
August 11, 2026 PDF Version Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee (DMC) following a prespe
Read more
Report
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board
August 10, 2026 PDF Version Experienced Merck researcher will expand the Board's drug discovery expertise MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) - Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
4
Hiring now
3
Countries
1
Busiest office
Jersey City
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Hayward
United States
HQ
Z Hayward, California - Do Not Use
Jersey City
United States
Eikon Therapeutics - HQ CA
13 open roles 13 posted in 90 days 23% engineering $236k Avg Salary
hires for Biotech, Science & Research, Early Careers
New York
United States
Regional office
New York, New York
2 open roles 1 posted in 90 days
hires for Early Careers
Millbrae
United States
Regional office
Start a Conversation
1 open roles 13 posted in 90 days
hires for Early Careers
230 Harriet Tubman Way, Millbrae, CA 94030